MLR Maelor

RNS Number:3249P
Maelor PLC
27 July 2005

27th July 2005

AGM STATEMENT AND ACQUISITION OF PRODUCT RIGHTS

Alastair Macpherson, Chairman of Maelor plc, will make the following statement
at today's AGM:

"The past financial year has seen another twelve months of steady progress for
your Company.  Turnover increased by 22% and losses were substantially reduced.
A year ago we stated that we believed that we had sufficient funds to see the
Company through to profitability.  Since the interim statement in November 2004
our cash resources have increased, thus underlining the future viability of our
business, and indicating progress towards profitability.

One of the most significant achievements of the past year was securing marketing
approval for ContiSol(R), our range of urethral catheter cleansing products, in
Canada.  We have appointed American Australian Medical, Inc, as our partner for
North America, and they have launched ContiSol in Canada this month.  We are
also working with them on the necessary submissions that need to be made in the
United States, the world's biggest medical devices market.

OptiFlo(R), the brand name of our urethral catheter cleansing products sold by
Bard Limited, has again made good progress, and its share of the UK community
prescriptions market stands at a new high of 46%, compared with 42% in 2004.

We are pleased to announce today that Maelor is taking a significant step
towards becoming a fully integrated healthcare company.  We have reached
agreement with Cambridge Laboratories Limited (Cambridge) to re-acquire the
marketing rights to Volplex(R), our blood plasma volume substitute, following
its successful launch in the UK by Cambridge.  I can report that the two
companies have agreed to ensure a smooth handover as soon as the necessary
regulatory approvals are granted. There will be some set-up costs which will
impact in this financial year, but with an established market presence and good
relationships in place with key customers, Maelor expects to sustain market
share for Volplex with a small investment in extra resources.  We will also be
seeking to add further products to our portfolio over time, potentially as a
result of our continued good working relationship with Cambridge.

Bringing this successful product back to Maelor is intended to accelerate our
progress towards profitability, and marks an important milestone in our growth
into a mature healthcare company.  Maelor intends to attract new and innovative
products to build on the substantial growth that we have been experiencing over
the past three years, during which time we have almost trebled sales.  Maelor is
approaching its 2005/6 financial year with confidence, and plans to continue its
drive to profitability."

                                     -ends-

For further information:

Maelor plc          Stephen Appelbee, Chief Executive Officer Tel: 01978 810 153
Financial Dynamics  Ben Atwell / Lucy Briggs                  Tel: 0207 831 3113


Notes to Editors

Maelor plc

Maelor is an AiM-listed specialist healthcare products company. The company has
several products on the market including OptiFlo, ContiSol and Volplex.

OptiFlo, a urethral catheter maintenance range, launched in the UK in June 1999
and distributed through Bard Limited, has gained a 46% share of the UK community
prescription market (source: IMS).

ContiSol, Maelor's own-brand urethral catheter maintenance range, has already
been launched in Canada (by American Australoian Medical Inc.), in Spain (by
CAIR Espana SL) and in Greece (by M. S. Jacovides SA).

Volplex, the company's blood plasma volume substitute, is used for patients
suffering from the effects of trauma, surgery or certain medical conditions
which result in hypovolaemia (lower than normal blood volume).

Maelor has various products under development including micelle propofol, a
reformulation of the world's biggest-selling general anaesthetic.

Volplex(R) and ContiSol(R) are trademarks of Maelor Pharmaceuticals Limited

OptiFlo(R) is a trademark of Bard Limited


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
AGMSEIFLMSISELW

Maelor (LSE:MLR)
Historical Stock Chart
From Jun 2024 to Jul 2024

Maelor (LSE:MLR)
Historical Stock Chart
From Jul 2023 to Jul 2024